April 27 (Reuters) – Intellia Therapeutics said on Monday its experimental therapy for a rare genetic disorder has met the main goal in a late-stage study.
(Reporting by Kunal Das; Editing by Vijay Kishore)
Intellia Therapeutics’ rare genetic disorder therapy meets main goal in trial
Apr 27, 2026 | 7:06 AM
Comments